IL17A and histiocytic sarcoma: After 36 weeks of adalimumab therapy, Th17 lymphocyte- and neutrophil-related inflammatory serum markers (IL-1β, IL-6, IL-8, IL-10, IL-17A, soluble TNF receptor I (sTNF-RI), sTNF-RII, CRP, and ESR) decreased significantly in HS patients [125].